Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pulmonx (LUNG) EBT (2019 - 2025)

Pulmonx (LUNG) has disclosed EBT for 7 consecutive years, with -$13.8 million as the latest value for Q3 2025.

  • On a quarterly basis, EBT rose 0.88% to -$13.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$56.3 million, a 0.22% change, with the full-year FY2024 number at -$55.9 million, up 7.26% from a year prior.
  • EBT was -$13.8 million for Q3 2025 at Pulmonx, up from -$15.0 million in the prior quarter.
  • In the past five years, EBT ranged from a high of -$10.1 million in Q3 2021 to a low of -$16.1 million in Q2 2023.
  • A 5-year average of -$14.0 million and a median of -$14.0 million in 2022 define the central range for EBT.
  • Peak YoY movement for EBT: crashed 165.99% in 2021, then rose 13.81% in 2024.
  • Pulmonx's EBT stood at -$12.9 million in 2021, then decreased by 9.2% to -$14.0 million in 2022, then grew by 2.83% to -$13.6 million in 2023, then increased by 3.69% to -$13.1 million in 2024, then fell by 5.27% to -$13.8 million in 2025.
  • Per Business Quant, the three most recent readings for LUNG's EBT are -$13.8 million (Q3 2025), -$15.0 million (Q2 2025), and -$14.3 million (Q1 2025).